Results 91 to 100 of about 8,866 (177)

The new Bruton’s tyrosine kinase inhibitors SPA8007 and SPA8009 reduce stemness and invasiveness of patient-derived glioblastoma tumorspheres

Translational Oncology
Glioblastoma (GBM), the most prevalent primary brain tumor, remains incurable due to the presence of cancer stem cells (CSCs), which can be isolated as tumorspheres (TSs) that exhibit classical characteristics of CSCs, including stemness and invasiveness.
Euna Jo, Eun Lee, Yoojung Oh, Dongkyu Lee, Byungho Lee, Kibyeong Kim, Ran Joo Choi, Jiyun Hong, Yuesong Jeon, Hyewon Cho, Yong-Sung Choi, Sangwoo Kim, So Young Won, Seonah Choi, Tae Hoon Roh, Ju Hyung Moon, Eui Hyun Kim, Jong Hee Chang, Raok Jeon, Seok-Gu Kang   +19 more
doaj   +1 more source

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma [PDF]

, 2015
Multiple Myeloma (MM) is a haematologic malignancy characterized by the accumulation of clonal plasma cells in the bone marrow. Over the last 10-15 y the introduction of the proteasome-inhibitor bortezomib has improved MM prognosis, however relapse due ...
American Cancer Society, David J MacEwan, Jenny IO Craig, Kristian M Bowles, Lyubov Zaitseva, Martin J Auger, Megan Y Murray, O'Brien S, Stuart A Rushworth, Taverna C   +9 more
core   +1 more source

Overcoming challenges in CAR‐T therapy for malignancies: Mechanisms and strategies

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
Chimeric antigen receptor T (CAR‐T) cell therapy faces three major challenges: tumour‐intrinsic resistance mechanisms, limitations in CAR‐T cell efficacy and immunosuppressive tumour microenvironment (TME) effects. Emerging strategies address these hurdles through precision targeting enhancement, optimised CAR‐T cell persistence/functionality and TME ...
Yushan Huang, Jun Long, Changpeng Yang, Wang Lu, Husheng Mei, Wenbin Qian, Jing Yang, Aibin Liang   +7 more
wiley   +1 more source

Alterations in Gut Microbiota and Metabolic Profiles in Relapsed or Refractory Lymphoma

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Metabolomic volcano‐heatmap reveals seven upregulated metabolites in relapsed/refractory lymphoma, underscoring gut metabolic reprogramming as a potential therapeutic target. ABSTRACT To identify potential therapeutic strategies for relapsed or refractory lymphoma (R/RL) by examining differences in gut microbiota composition and metabolic profiles ...
Yu‐Ying Guo, Kang‐Jing Xue, Liao Wang, Gang‐Gang Wang, Ting‐Ting Zhang, Shu‐Ling Hou   +5 more
wiley   +1 more source

The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]

, 2019
Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core  

Tumor‐Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation

MedComm, Volume 7, Issue 2, February 2026.
Tumor‐associated macrophages are the most abundant immune cells in the tumor microenvironment, driving malignant progression and treatment resistance. This review summarizes the protumor mechanisms of TAMs (including phagocytosis modulation, metabolic reprogramming, exosomal communication, and immune interactions), evaluates three major strategies ...
Wurihan Bao, Xiaojie Qu, Yiqi Wang, Dan Huang, Huiling Zhang, Mingyuan Dong, Han Sun, Zhaogang Yang, Xuefeng Li   +8 more
wiley   +1 more source

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma

Journal of Experimental & Clinical Cancer Research, 2017
Background Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. Ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, is a novel anticancer drug used for treating several types of cancers.
Jin Wang, Xiaoyang Liu, Yongzhi Hong, Songtao Wang, Pin Chen, Aihua Gu, Xiaoyuan Guo, Peng Zhao   +7 more
doaj   +1 more source

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, Volume 116, Issue 2, Page 104-115, February 2026.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia

eLife
Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders, and multiple sclerosis. Since the approval of the first BTK inhibitor
Raji E Joseph, Thomas E Wales, Sandrine Jayne, Robert G Britton, D Bruce Fulton, John R Engen, Martin JS Dyer, Amy H Andreotti   +7 more
doaj   +1 more source

T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions

European Journal of Haematology, Volume 116, Issue 2, Page 129-141, February 2026.
ABSTRACT Relapsed/refractory (R/R) mantle cell lymphoma (MCL) remains a therapeutic challenge, particularly in patients with high‐risk features or prior exposure to Bruton's tyrosine kinase inhibitors (BTKis). The advent of T‐cell–redirecting immunotherapies, including chimeric antigen receptor T‐cell (CAR‐T) therapy and bispecific antibodies (BsAbs ...
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source